Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer

被引：0
|
作者：
Hindie, Elif [1 ]
机构：
[1] CHU Bordeaux, Dept Nucl Med, Hop Haut Leveque, Ave Magellan, F-33604 Pessac, France
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E425 / E425
页数：1
相关论文
共 50 条
  • [1] 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer
    Sanli, Yasemin
    Simsek, Duygu Has
    Sanli, Oner
    Subramaniam, Rathan M.
    Kendi, Ayse Tuba
    [J]. BIOMEDICINES, 2021, 9 (04)
  • [2] Perspective on 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer
    Kwekkeboom, Dik
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) : 1002 - 1003
  • [3] High Activity 177Lu-PSMA Therapy Of Metastatic Castration-resistant Prostate Cancer
    Happel, C.
    Kranert, W. T.
    Bockisch, B.
    Groener, D.
    Davis, K. H.
    Wichert, J.
    Stefanova, M.
    Gruenwald, F.
    Sabet, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S647 - S648
  • [4] 177Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
    Derlin, Thorsten
    Widjaja, Liam
    Werner, Rudolf A.
    Bengel, Frank M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (01) : 54 - 58
  • [5] Liver Enzyme Elevation After 177Lu-PSMA Radioligand Therapy for Metastasized Castration-Resistant Prostate Cancer
    Treiber, Hannes
    Koenig, Alexander
    Neesse, Albrecht
    Richter, Annika
    Sahlmann, Carsten Oliver
    Strauss, Arne
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (07) : 1016 - 1019
  • [6] 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation
    Assadi, Majid
    Pirayesh, Elahe
    Rekabpour, Seyed Javad
    Zohrabi, Farshad
    Jafari, Esmail
    Nabipour, Iraj
    Esmaili, Abdolhamid
    Amini, Abdullatif
    Ahmadzadehfar, Hojjat
    [J]. CLINICAL NUCLEAR MEDICINE, 2019, 44 (12) : 978 - 980
  • [7] Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Ling, Sui Wai
    de Blois, Erik
    Hooijman, Eline
    van der Veldt, Astrid
    Brabander, Tessa
    [J]. PHARMACEUTICS, 2022, 14 (10)
  • [8] Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
    Gafita, Andrei
    Calais, Jeremie
    Grogan, Tristan R.
    Hadaschik, Boris
    Wang, Hui
    Weber, Manuel
    Sandhu, Shahneen
    Kratochwil, Clemens
    Esfandiari, Rouzbeh
    Tauber, Robert
    Zeldin, Anna
    Rathke, Hendrik
    Armstrong, Wesley R.
    Robertson, Andrew
    Thin, Pan
    D'Alessandria, Calogero
    Rettig, Matthew B.
    Delpassand, Ebrahim S.
    Haberkorn, Uwe
    Elashoff, David
    Herrmann, Ken
    Czernin, Johannes
    Hofman, Michael S.
    Fendler, Wolfgang P.
    Eiber, Matthias
    [J]. LANCET ONCOLOGY, 2021, 22 (08): : 1115 - 1125
  • [9] Treatment efficacy and safety of 177Lu-PSMA Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer
    Langbein, T.
    Retz, M.
    D'Alessandria, C.
    Grigorascu, S.
    Hansen, K.
    Wester, H.
    Gschwend, J.
    Weber, W.
    Eiber, M.
    Tauber, R.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S132 - S133
  • [10] Care Pathway at a Cancer Center for the Administration of Radiometabolic Therapy with 177Lu-PSMA in Patients with Metastatic Castration-resistant Prostate Cancer
    Avila, Carlos
    Cadavid, Tatiana
    Martinez, Maria Cristina
    Varela, Humberto
    Hernandez-Hidalgo, Nathalie
    [J]. MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2024, 33 (01) : 28 - 37
12345